Patient-Reported Symptoms Over 48 Weeks Among Participants in Randomized, Double-Blind, Phase III Non-inferiority Trials of Adults with HIV on Co-formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Co-formulated Abacavir, Dolutegravir, and Lamivudine

BACKGROUND: Integrase strand transfer inhibitors (INSTIs) are recommended for first-line antiretroviral therapy in combination with two nucleos(t)ide reverse transcriptase inhibitors. Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide (B/F/TAF), a novel, INSTI-based regimen, is curr...

Descripción completa

Detalles Bibliográficos
Autores principales: Wohl, David, Clarke, Amanda, Maggiolo, Franco, Garner, Will, Laouri, Marianne, Martin, Hal, Quirk, Erin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6132439/
https://www.ncbi.nlm.nih.gov/pubmed/29956087
http://dx.doi.org/10.1007/s40271-018-0322-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6132439/
https://www.ncbi.nlm.nih.gov/pubmed/29956087
http://dx.doi.org/10.1007/s40271-018-0322-8

Ejemplares similares